Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Gilead Sciences receives EU approval for HIV drug Vitekta

Gilead Sciences receives EU approval for HIV drug Vitekta

22nd November 2013

Gilead Sciences has been granted European regulatory approval for Vitekta, a tablet-based integrase inhibitor therapy for HIV.

The drug has been ratified by the European Commission for use in the treatment of HIV-1 infections in adults without known mutations associated with resistance to elvitegravir. It is indicated for use in therapy regimens that include a ritonavir-boosted protease inhibitor.

Vitekta interferes with HIV replication by blocking the virus from integrating into the genetic material of human cells and has been shown to be effective in suppressing HIV among patients with drug-resistant strains of the disease.

Dr Norbert Bischofberger, executive vice-president for research and development and chief scientific officer at Gilead Sciences, said: "Vitekta is only the second integrase inhibitor to become available in the European Union. Today's approval exemplifies Gilead's ongoing commitment to meeting the evolving needs of people living with HIV."

This comes after the company received EU approval for the combination HIV therapy Stribild earlier this year. Vitekta is one of the four compounds included in the formulation of Stribild.ADNFCR-8000103-ID-801663864-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.